56 percent drop in lung pressure seen with new inhaled therapy for rare disease
A new inhaler targets an under-the-radar lung condition with surprising results.
Let’s start with the basics. Your body is designed to breathe effortlessly. But when that rhythm gets disrupted, every other part of your life feels the impact. We often take our respiratory system for granted until it starts to struggle. Today we are looking at a scientific breakthrough that addresses a quiet but severe health challenge. This is not about exotic superfoods or trendy juices. This is about fundamental biology and how we can support it.
Researchers in Germany have been working on this for years. They are exploring a pathway known as the nitric oxide, sGC, cGMP pathway. The idea is simple but the execution took decades. The work began with the German Center for Lung Research and the Institute for Lung Health in Giessen. Their goal was to understand how to help the lungs function better when they are damaged.
Think of this process like a complex mechanical valve system in your plumbing. Soluble guanylate cyclase, or sGC, is like that valve. It helps regulate blood flow in the lungs. When the tissue gets inflamed or scarred, that valve can break down. It stops working properly because it loses the tools it needs. Specifically, it can become heme-free. This is where the concept of sGC activators comes in. These are different from simple stimulators.
Stimulators act on the healthy parts of the valve. Activators, however, are designed to work when the valve is broken or rusty. They target the forms of the enzyme that accumulate under oxidative stress. This is crucial for people with interstitial lung disease. This condition involves scarring of the lung tissue. It is a difficult diagnosis to manage but the research community is making strides.
Enter mosliciguat. This is an investigational inhaled drug. It is delivered as a dry-powder inhalation. This method is practical because it targets the problem right where it happens. It aims to restore cGMP signaling locally in the lungs. This limits the drug traveling through the rest of the body, which reduces side effects. The concept has a long history. In fact, earlier collaborative work between researchers in Giessen and scientists working with Johannes-Peter Stasch at Bayer led to the development of riociguat. That success was recognized with the prestigious 2015 German Future Prize of the Federal President.
The first real-world proof of this concept was the ATMOS study. This phase 1b trial involved patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. The results were encouraging. There was a sustained reduction in pulmonary vascular resistance after just one dose. Most side effects were mild. Crucially, there were no safety-related changes in blood pressure or systemic vascular resistance. These findings paved the way for a much larger test called PHocus.
PHocus was a randomized double-blind placebo-controlled study. It sounds clinical, but the impact is human. The study enrolled 135 adults with pulmonary hypertension associated with interstitial lung disease. There were 87 centers across 20 countries. This is a global effort to solve a local problem. At week 16, the study met its primary endpoint with a 56.3 percent placebo-adjusted reduction in pulmonary vascular resistance. This is a significant number. It suggests the drug is physically changing the resistance in the blood vessels.
The effect was consistent. It favored mosliciguat across all subgroups. This included different forms of the underlying interstitial lung disease and the degree of the pulmonary vascular disease. Even patients on antifibrotic treatment and those using or not using PDE5 inhibitors saw benefits. The hemodynamic improvement was accompanied by a tangible gain in exercise capacity. This is often the most important metric for patients. The six-minute walking distance improved by 35.2 meters or 115 feet versus placebo at week 16. In a follow-up exploratory analysis, the placebo-adjusted difference increased further to 52.7 meters or 173 feet at week 24.
Improvement was also seen in NT-proBNP and other measures of right-heart and pulmonary vascular function. Werner Seeger and Ardeschir Ghofrani highlighted the continuity of this science. Dr. Ghofrani noted that PH-ILD remains a disease with a high medical need. He emphasized that the consistency of the effect across groups is encouraging. Friedrich Grimminger pointed out that this represents the value of implementing scientific findings through hospital networks. These networks, developed over decades, are vital for rare diseases.
We cannot ignore the heart connection. Khodr Tello explained that in lung fibrosis patients, vascular abnormalities contribute to the development of pulmonary hypertension. This then negatively affects the right ventricle. This can lead to myocardial remodeling and maladaptation. This is a major determinant of prognosis. An echocardiographic subgroup analysis examined this sequence in detail.
The next step is already underway. The global PHrontier phase 3 trial is recruiting. Approximately 375 patients with PH-ILD are planned to be randomly assigned to receive mosliciguat or placebo. The primary endpoint is the change in six-minute walking distance after 24 weeks. Key secondary outcomes include time to clinical worsening, pulmonary vascular resistance, and NT-proBNP. This marks a milestone in translating a fundamental physiological pathway into a real-world treatment.
While mosliciguat remains an investigational drug and has not been approved for the treatment of PH-ILD, the trajectory is clear. This research represents the kind of long-term bench-to-bedside work that institutions like the Institute for Lung Health exist to enable. For the millions who struggle to breathe easily every day, these steps represent hope.
First reported by Medical Xpress.
More in Health & Nutrition
- Long-term opioid use fails to alleviate chronic back pain, Northwestern University study suggests
Researchers identified distinct brain activity patterns and molecular markers that may guide future treatments for pain management and opioid tapering.
- Human tau seeds trigger disease-specific shapes in mouse brains, new study finds
Study in Nature shows that injectable human tau aggregates from Alzheimer’s and corticobasal degeneration template their 3D folds onto mouse tau, supporting the prion-like seeding model.
- Menopause Largely Missing from Electronic Health Records Despite Its Health Impact
study of nearly 240,000 women finds only 12% of electronic records include menopause status, even though over half reported being in transition.